Matching articles for "apixaban"
Issue 1757 · June 22, 2026 Free
In Brief: Apixaban vs Rivaroxaban for Acute VTE

The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban ( Xarelto , and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at…

Med Lett Drugs Ther. 2026 Jun 22; 68(1757):103 doi:10.58347/tml.2026.1757f
The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban ( Xarelto , and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at least 3 months. The other DOACs (edoxaban [Savaysa] and dabigatran [ Pradaxa , and generics]) are alternatives for long-term treatment, but they require prior treatment with low-molecular-weight heparin for ≥5 days. Until recently, no large randomized trial directly comparing the safety of apixaban and rivaroxaban for treatment of VTE was available.
Issue 1746 · January 19, 2026 Free
In Brief: Andexanet alfa (Andexxa) Withdrawn

Andexanet alfa ( Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):16 doi:10.58347/tml.2026.1746f
Andexanet alfa ( Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto) , has voluntarily been withdrawn from the market. Andexxa was the only drug FDA-approved for this indication in the US.
Issue 1693 · January 8, 2024
Treatment of Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of…

Med Lett Drugs Ther. 2024 Jan 8; 66(1693):1-8 doi:10.58347/tml.2024.1693a
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Issue 1655 · July 25, 2022
Drugs for Treatment and Prevention of Venous Thromboembolism

Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for…

Med Lett Drugs Ther. 2022 Jul 25; 64(1655):113-20
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Issue 1655 · July 25, 2022
Comparison Table: Some Oral Anticoagulants for VTE (online only)

View the Comparison Table: Some Oral Anticoagulants for VTE

Med Lett Drugs Ther. 2022 Jul 25; 64(1655):e122-4
View the Comparison Table: Some Oral Anticoagulants for VTE
Issue 1580 · September 9, 2019
Drugs for Atrial Fibrillation

Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.

Med Lett Drugs Ther. 2019 Sep 9; 61(1580):137-44
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
Issue 1549 · June 18, 2018
Andexxa - An Antidote for Apixaban and Rivaroxaban

Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):99-101
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto) . Andexanet alfa is the second antidote for a direct oral anticoagulant to become available in the US, and the fi rst for factor Xa inhibitors. Idarucizumab (Praxbind) was approved in 2015 for reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa) . Andexanet alfa has not been approved to date for reversal of anticoagulation with the direct factor Xa inhibitors edoxaban (Savaysa) or betrixaban (Bevyxxa) .
Issue 1542 · March 12, 2018
Drugs for Treatment and Prevention of Venous Thromboembolism

Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). Updated US guidelines…

Med Lett Drugs Ther. 2018 Mar 12; 60(1542):41-8
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). Updated US guidelines for treatment of VTE were published in 2016.
Issue 1542 · March 12, 2018
Comparison Table: Some Oral Anticoagulants for VTE (online only)

View the Comparison Table: Some Oral Anticoagulants for VTE

Med Lett Drugs Ther. 2018 Mar 12; 60(1542):e51-4
View the Comparison Table: Some Oral Anticoagulants for VTE
Issue 1537 · January 1, 2018
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness

The FDA has approved betrixaban ( Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who…

Med Lett Drugs Ther. 2018 Jan 1; 60(1537):4-5
The FDA has approved betrixaban ( Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have moderately or severely restricted mobility and other risk factors for VTE. Betrixaban is the first oral anticoagulant to be approved in the US for this indication.
Issue 1521 · May 22, 2017 Free
Prescription Drug Prices in the US

Per capita spending on prescription drugs in the US is higher than in other industrialized nations, including Canada.

Med Lett Drugs Ther. 2017 May 22; 59(1521):81-3
Per capita spending on prescription drugs in the US is higher than in other industrialized nations, including Canada.
Issue 1515 · February 27, 2017
Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation

With the widespread adoption of the CHA 2 DS 2 -VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation. Atrial fibrillation…

Med Lett Drugs Ther. 2017 Feb 27; 59(1515):35-6
With the widespread adoption of the CHA 2 DS 2 -VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation. Atrial fibrillation has, however, been associated with an increased risk of falls, and older patients starting warfarin for atrial fibrillation have a high rate of hospitalization for intracranial bleeding. Many practitioners are reluctant, therefore, to prescribe an oral anticoagulant for elderly patients who are at high risk for falls.
Issue 1492 · April 11, 2016
Which Oral Anticoagulant for Atrial Fibrillation?

Direct-to-consumer advertisements continue to urge patients who take warfarin ( Coumadin , and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral…

Med Lett Drugs Ther. 2016 Apr 11; 58(1492):45-6
Direct-to-consumer advertisements continue to urge patients who take warfarin ( Coumadin , and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral anticoagulants.
Issue 1482 · November 23, 2015
Idarucizumab (Praxbind) - An Antidote for Dabigatran

The FDA has approved idarucizumab ( Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa) . Idarucizumab is the…

Med Lett Drugs Ther. 2015 Nov 23; 57(1482):157-8
The FDA has approved idarucizumab ( Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa) . Idarucizumab is the first specific reversal agent to become available for one of the new oral anticoagulants.
Issue 1465 · March 30, 2015
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

The FDA has approved edoxaban ( Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in…

Med Lett Drugs Ther. 2015 Mar 30; 57(1465):43-5
The FDA has approved edoxaban ( Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Issue 1454 · October 27, 2014
Antithrombotic Drugs

Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention…

Med Lett Drugs Ther. 2014 Oct 27; 56(1454):103-8
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Issue 1446 · July 7, 2014
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Issue 1433 · January 6, 2014
New Oral Anticoagulants for Acute Venous Thromboembolism

Anticoagulants are the drugs of choice for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE).

Med Lett Drugs Ther. 2014 Jan 6; 56(1433):3-4
Anticoagulants are the drugs of choice for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE).
Issue 1426 · September 30, 2013
Rethinking Warfarin for Atrial Fibrillation

Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis (apixaban – Bristol-Myers Squibb). Apixaban is…

Med Lett Drugs Ther. 2013 Sep 30; 55(1426):77
Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis (apixaban – Bristol-Myers Squibb). Apixaban is the latest of 3 new oral anticoagulants now competing with warfarin ( Coumadin , and others) for the oral anticoagulant market.
Issue 1420 · July 8, 2013
Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation

The FDA has approved use of Kcentra (CSL Behring), a human-derived 4-factor prothrombin complex concentrate (PCC), for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. It is the…

Med Lett Drugs Ther. 2013 Jul 8; 55(1420):53-4
The FDA has approved use of Kcentra (CSL Behring), a human-derived 4-factor prothrombin complex concentrate (PCC), for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. It is the only 4-factor PCC available in the US.
Issue 1409 · February 4, 2013
Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation

The FDA has approved apixaban ( Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor, for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It…

Med Lett Drugs Ther. 2013 Feb 4; 55(1409):9-10
The FDA has approved apixaban ( Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor, for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the third new oral anticoagulant to be approved for this indication as an alternative to warfarin.
Issue 1400 · October 1, 2012
Choice of an Oral Anticoagulant in Atrial Fibrillation

Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulant therapy can reduce this risk and is recommended for patients with atrial fibrillation and one or more of the following: congestive…

Med Lett Drugs Ther. 2012 Oct 1; 54(1400):79-80
Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulant therapy can reduce this risk and is recommended for patients with atrial fibrillation and one or more of the following: congestive heart failure, hypertension, age ≥75 years, diabetes, or prior stroke or transient ischemic attack (CHADS 2 score ≥1).
Issue 110 · October 1, 2011
Antithrombotic Drugs

Arterial thrombi are composed mainly of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but…

Treat Guidel Med Lett. 2011 Oct; 9(110):61-6
Arterial thrombi are composed mainly of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but anticoagulants are also effective, and their effects can add to those of antiplatelet drugs. Venous thrombi are composed mainly of fibrin and trapped red blood cells, with relatively few platelets. Anticoagulants are the agents of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.